Register for our free email digests:
Juno Therapeutics Inc.
Division of Bristol-Myers Squibb Co.
www.junotherapeutics.com
Latest From Juno Therapeutics Inc.
ASH First Look: CAR-T Therapies Against BCMA, CD19 And More
CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.
GSK's Hal Barron On R&D Progress At Two-Year Mark
Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Culture Change At GSK: 'We’re Doing What We Said We’d Do'
Chief scientific offficer Hal Barron talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
-
Hans Bishop, Pres. & CEO
Steven D Harr, MD, Head, Corp. Dev. & CFO
Hyam I Levitsky, MD, EVP, CSO
Sunil Agarwal, MD, Pres., R&D - Contact Info
-
Juno Therapeutics Inc.
Phone: (206) 582-1600
400 Dexter Ave. North
Ste. 1200
Seattle, WA 98109
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice